<DOC>
	<DOC>NCT00092105</DOC>
	<brief_summary>The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.</brief_summary>
	<brief_title>Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)</brief_title>
	<detailed_description>The duration of treatment is 2 weeks.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Increased sensitivity to cat allergen proven by positive allergy testing, and by decreased lung function and increased symptoms of allergic rhinitis (runny nose) upon exposure to cats. Medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rhinitis, Allergic</keyword>
</DOC>